atai Life Sciences to Participate in Upcoming Investor Conferences
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health treatments, has announced its participation in two upcoming investor conferences in June 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health treatments, has announced its participation in two upcoming investor conferences in June 2025. The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5 at 9:55 A.M. EDT in New York. Additionally, atai will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference through a pre-recorded fireside chat on June 17 at 7:00 A.M. EDT in a virtual format. Both presentations will be available via webcast on the company's investor relations website, with replays available after the events.
Details
News Market Reaction – ATAI
The recorded move for ATAI in the trading session of this news was +0.43%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that the Company’s management team is scheduled to participate in the following investor conferences in June:
Jefferies Global Healthcare Conference
- Format: Fireside Chat
- Date and Time: Thursday, June 5 at 9:55 A.M. EDT
- Location: New York
- Webcast link: here
H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
- Format: Pre-recorded Fireside Chat
- Date and Time: Tuesday, June 17 at 7:00 A.M. EDT
- Location: Virtual
- Webcast link: here
The webcasts of the fireside chats will also be available on the Investors section of the atai website under Events. A replay will be available following the live event.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Our pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. We are also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about our mission, visit www.atai.com or follow us on LinkedIn.
Contact Information
Investor Contact:
IR@atai.com
Media Contact:
PR@atai.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.